HealthDay News — Drugmaker Eli Lilly plans to buy Verve Therapeutics, a gene-editing startup, for about $1 billion upfront. The deal gives Lilly a potential new treatment for heart disease, The Wall ...

Eli Lilly's orforglipron reduced A1C and weight in type 2 diabetes, while weekly insulin efsitora matched daily insulin with fewer side effects.

Eli Lilly’s $1.3 billion acquisition of Verve Therapeutics marks a strategic expansion into cardiovascular genetic medicine. The pharmaceutical giant paid a premium of about 113% over Verve’s ...

In light of the recent options history for Eli Lilly, it's now appropriate to focus on the company itself. We aim to explore its current performance. Current Position of Eli Lilly Currently ...

As Her Spectacular Career Winds Down, a Look at the Excellence of Lilly King It’s official: Lilly King is retiring. The three-time Olympian and breaststroke legend announced in a May 31 ...

In practical terms, this leads to more stable blood sugar levels and improved A1C results over time. For many, Trulicity is also associated with modest weight loss, a valuable added benefit in ...

soccer Hingham’s Lilly Reale named to national women’s soccer team training camp roster By Emma Healy Globe Staff,Updated June 18, 2025, 2:31 p.m.

Eli Lilly acquires Verve Therapeutics, Inc. for $1B to advance gene-editing therapies like VERVE-102, targeting ASCVD. Click for more on LLY and VERV.

For further discussion of these and other risks and uncertainties, see Lilly's and Verve's most recent Form 10-K and Form 10-Q filings with the U.S. Securities and Exchange Commission.

Patients who took an experimental drug from Eli Lilly and Co. together with Novo Nordisk A/S’s Wegovy maintained muscle while losing weight, offering a potential solution to one of the key ...

Lilly to buy gene-editing partner Verve for up to $1.3 billion in cardiac care push Jun 16, 2025 Updated Jun 17, 2025 ...